Diroximel fumarate to treat multiple sclerosis.
Sign Up to like & getrecommendations! Published in 2020 at "Drugs of today"
DOI: 10.1358/dot.2020.56.7.3151521
Abstract: On October 29, 2019, the Food and Drug Administration (FDA) of the United States approved diroximel fumarate (DRF) as an oral fumarate for the treatment of relapsing forms of multiple sclerosis. Another oral fumarate, dimethyl… read more here.
Keywords: diroximel fumarate; fumarate; multiple sclerosis; treat multiple ... See more keywords
Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data
Sign Up to like & getrecommendations! Published in 2022 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s236926
Abstract: Abstract Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and neurodegenerative disorder of the central nervous system. Disease-modifying drugs (DMDs) and subsequent adherence are crucial for preventing reversible episodes of neurological dysfunction and delayed onset… read more here.
Keywords: fumarate novel; relapsing forms; therapy; diroximel fumarate ... See more keywords